SOURCE: Xtalks

Xtalks Webinars

November 06, 2015 07:30 ET

Targeted Sequencing as a Tool to Understand the Genetic Basis of Transplant Rejection

TORONTO, ON--(Marketwired - November 06, 2015) - On Tuesday, November 17, 2015, a new webinar presented by Roche NimbleGen (hosted by Xtalks), will discuss Targeted Sequencing as a Tool to Understand the Genetic Basis of Transplant Rejection and the panel Roche NimbleGen has designed. The keynote speaker will be Dr. Brendan J. Keating, Assistant Professor of Pediatrics and Surgery, Perelman School of Medicine, University of Pennsylvania.

Solid organ transplantation has become a common procedure, however the risk of graft organ rejection is an ever present danger. While there has been significant progress with immuno-suppression therapies, there is still significant risk of graft organ rejection, even when appropriate HLA matching has been performed. For instance, transplant rejection rates are much higher in cases when the donor and recipient are of the same sex, or of different ethnic backgrounds. This and large scale epidemiological and other datasets suggest that additional genetic factors are at play in allograft rejection processes. Possible sources of genetic variation underpinning rejection are homozygous deletion copy number variants (CNVs) spanning whole gene or exon regions and Loss of Function (LoF) variants ablating two copies of a given gene, resulting in incompatibility across the proteomes of donor and recipient. It has been shown through large-scale whole genome sequencing studies that the average human has 20 genes disrupted (i.e. with LoF) in two copies1.

Roche NimbleGen has designed a panel to capture 6.5 Mb of DNA, targeting over 300 hdCNVs and non-exonic PGx content, and spiked it into the 64Mb SeqCap EZ Exome Enrichment Kit v3.0 whole exome capture product (Roche NimbleGen). DNA from over 500 tissue and blood samples from transplant donors and recipients (including lung, liver, heart and kidney) within the NIH prospective Clinical Trials in Organ Transplantation-03 (CTOT-03) study were subjected to the 70.5Mb capture tool followed by SGS on HiSeq2000 (Illumina). A comparison of hdCNV and LoF carriages across the entire donor pool will be done along with the entire recipient pool in order to assess inherent differences between these two populations. Custom probes for dozens of putative candidate allogenic targets were then brought forward for screening on a transplant specific 175,000 peptide array tool (Roche NimbleGen).

To register or learn more about this complimentary event visit: Targeted Sequencing as a Tool to Understand the Genetic Basis of Transplant Rejection

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

1. MacArthur et al, Science 335, 823 (2012). A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes

Unless explicitly stated otherwise, all Roche products and services referenced in this presentation/document are intended for the following use: For life science research only. Not for use in diagnostic procedures. SEQCAP is a trademark of Roche. All other product names and trademarks are the property of their respective owners.



Image Available: http://www.marketwire.com/library/MwGo/2015/11/5/11G070771/Images/ROCHE_logo-sm-438380682449.jpg

Contact Information